NCT04278092View on ClinicalTrials.gov

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel

Paclitaxel 175 mg/m2, q21

DRUG

Cetuximab

Cetuximab 400mg/m2 loading dose followed by weekly 250mg/m2

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT04278092 - Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | Biotech Hunter | Biotech Hunter